Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 169
Filtrar
1.
Rev Mal Respir ; 41(5): 331-342, 2024 May.
Artículo en Francés | MEDLINE | ID: mdl-38609767

RESUMEN

INTRODUCTION: The second COPD Biennial organized by the COPD working group of the French Society of Respiratory Diseases took place in Paris (Cochin) on 13th December 2023. STATE OF THE ART: Major trends in 2023 were discussed; they encompassed concepts, definitions, biologics, care pathways, pulmonary rehabilitation and complex situations entailed by respiratory infections, cardiovascular comorbidities and pulmonary hypertension, and modalities of oxygen therapy and ventilation. PERSPECTIVES: The different talks underlined major changes in COPD including the concepts of pre-COPD, etiotypes, health trajectories and new definitions of exacerbation. Recent results in biologics for COPD open the door to new pharmacological options. Assessment of current care pathways in France highlighted some causes for concern. For example, pulmonary rehabilitation is a key but insufficiently practiced element. Respiratory infections require careful assessment and treatments. Diagnosis and treatment of cardiovascular comorbidities and pulmonary hypertension are of paramount importance. As of late, oxygen therapy and ventilation modalities have evolved, and are beginning to afford more personalized options. CONCLUSIONS: As regards COPD, a personalized approach is crucial, placing the patient at the center of the care pathway and facilitating coordination between healthcare providers.


Asunto(s)
Vías Clínicas , Enfermedad Pulmonar Obstructiva Crónica , Sociedades Médicas , Humanos , Enfermedad Pulmonar Obstructiva Crónica/terapia , Enfermedad Pulmonar Obstructiva Crónica/epidemiología , Enfermedad Pulmonar Obstructiva Crónica/rehabilitación , Francia/epidemiología , Vías Clínicas/organización & administración , Vías Clínicas/normas , Vías Clínicas/tendencias , Sociedades Médicas/organización & administración , Sociedades Médicas/normas , Atención Dirigida al Paciente/organización & administración , Atención Dirigida al Paciente/tendencias , Atención Dirigida al Paciente/normas , Neumología/organización & administración , Neumología/tendencias , Neumología/métodos , Neumología/normas , Congresos como Asunto
3.
Mayo Clin Proc ; 96(5): 1250-1261, 2021 05.
Artículo en Inglés | MEDLINE | ID: mdl-33958056

RESUMEN

The administration of spike monoclonal antibody treatment to patients with mild to moderate COVID-19 is very challenging. This article summarizes essential components and processes in establishing an effective spike monoclonal antibody infusion program. Rapid identification of a dedicated physical infrastructure was essential to circumvent the logistical challenges of caring for infectious patients while maintaining compliance with regulations and ensuring the safety of our personnel and other patients. Our partnerships and collaborations among multiple different specialties and disciplines enabled contributions from personnel with specific expertise in medicine, nursing, pharmacy, infection prevention and control, electronic health record (EHR) informatics, compliance, legal, medical ethics, engineering, administration, and other critical areas. Clear communication and a culture in which all roles are welcomed at the planning and operational tables are critical to the rapid development and refinement needed to adapt and thrive in providing this time-sensitive beneficial therapy. Our partnerships with leaders and providers outside our institutions, including those who care for underserved populations, have promoted equity in the access of monoclonal antibodies in our regions. Strong support from institutional leadership facilitated expedited action when needed, from a physical, personnel, and system infrastructure standpoint. Our ongoing real-time assessment and monitoring of our clinical program allowed us to improve and optimize our processes to ensure that the needs of our patients with COVID-19 in the outpatient setting are met.


Asunto(s)
Antivirales/administración & dosificación , COVID-19 , Vías Clínicas , Terapia de Infusión a Domicilio , SARS-CoV-2 , Glicoproteína de la Espiga del Coronavirus , Anticuerpos Monoclonales/administración & dosificación , COVID-19/epidemiología , COVID-19/terapia , Protocolos Clínicos , Vías Clínicas/organización & administración , Vías Clínicas/tendencias , Eficiencia Organizacional , Terapia de Infusión a Domicilio/métodos , Terapia de Infusión a Domicilio/normas , Humanos , Colaboración Intersectorial , Cultura Organizacional , Desarrollo de Programa/métodos , SARS-CoV-2/inmunología , SARS-CoV-2/aislamiento & purificación , Índice de Severidad de la Enfermedad , Glicoproteína de la Espiga del Coronavirus/antagonistas & inhibidores , Glicoproteína de la Espiga del Coronavirus/inmunología , Estados Unidos/epidemiología
4.
Indian Pediatr ; 58(4): 383-390, 2021 Apr 15.
Artículo en Inglés | MEDLINE | ID: mdl-33883314

RESUMEN

JUSTIFICATION: The unprecedented COVID-19 pandemic has had a formidable impact on Indian health care. With no sight of its end as yet, various establishments including the smaller clinics and nursing homes are restarting full operations. Hence, there is the need for recommendations to allow safe practice ensuring the safety of both the heath care worker (HCW) and patients. PROCESS: Indian Academy of Pediatrics organized an online meeting of subject experts on 27 July, 2020. A committee was formed comprising of pediatricians, pediatric and neonatal intensivists, and hospital administrators. The committee held deliberations (online and via emails) and a final consensus was reached by November, 2020. OBJECTIVES: To develop recommendations to provide a safe and practical healthcare facility at clinics and small establishments during COVID times. RECOMMENDATIONS: The key recommendation to practise safely in this setting are enumerated. Firstly, organizing the out-patient department (OPD). Secondly, appropriate personal protective equipment (PPE) to provide protection to the individual. Thirdly, decontamination/disinfection of various common surfaces and equipment to prevent transmission of infection from fomites. Next, maintaining the heating ventilation and air conditioning (HVAC) to provide a stress-free, comfortable, and safe environment for patients and HCWs. Finally, steps to effectively manage COVID-19 exposures in a non-COVID-19 facility. All these measures will ensure safe practice during these unprecedent times in clinics and smaller establishments.


Asunto(s)
COVID-19 , Vías Clínicas , Control de Infecciones , Transmisión de Enfermedad Infecciosa de Paciente a Profesional/prevención & control , Neonatología , Pediatría , COVID-19/epidemiología , COVID-19/prevención & control , COVID-19/terapia , COVID-19/transmisión , Vías Clínicas/organización & administración , Vías Clínicas/normas , Vías Clínicas/tendencias , Humanos , India/epidemiología , Control de Infecciones/instrumentación , Control de Infecciones/métodos , Control de Infecciones/organización & administración , Colaboración Intersectorial , Neonatología/organización & administración , Neonatología/normas , Innovación Organizacional , Pediatría/organización & administración , Pediatría/normas , SARS-CoV-2 , Sociedades Médicas
5.
BMC Pregnancy Childbirth ; 21(1): 310, 2021 Apr 19.
Artículo en Inglés | MEDLINE | ID: mdl-33874913

RESUMEN

BACKGROUND: Induction of labour (IOL) is one of the most commonly performed interventions in maternity care, with outpatient cervical ripening increasingly offered as an option for women undergoing IOL. The COVID-19 pandemic has changed the context of practice and the option of returning home for cervical ripening may now assume greater significance. This work aimed to examine whether and how the COVID-19 pandemic has changed practice around IOL in the UK. METHOD: We used an online questionnaire to survey senior obstetricians and midwives at all 156 UK NHS Trusts and Boards that currently offer maternity services. Responses were analysed to produce descriptive statistics, with free text responses analysed using a conventional content analysis approach. FINDINGS: Responses were received from 92 of 156 UK Trusts and Boards, a 59% response rate. Many Trusts and Boards reported no change to their IOL practice, however 23% reported change in methods used for cervical ripening; 28% a change in criteria for home cervical ripening; 28% stated that more women were returning home during cervical ripening; and 24% noted changes to women's response to recommendations for IOL. Much of the change was reported as happening in response to attempts to minimise hospital attendance and restrictions on birth partners accompanying women. CONCLUSIONS: The pandemic has changed practice around induction of labour, although this varied significantly between NHS Trusts and Boards. There is a lack of formal evidence to support decision-making around outpatient cervical ripening: the basis on which changes were implemented and what evidence was used to inform decisions is not clear.


Asunto(s)
Actitud del Personal de Salud , COVID-19 , Maduración Cervical , Vías Clínicas , Trabajo de Parto Inducido , Adulto , Atención Ambulatoria/métodos , COVID-19/epidemiología , COVID-19/prevención & control , Toma de Decisiones Clínicas , Vías Clínicas/organización & administración , Vías Clínicas/tendencias , Femenino , Humanos , Control de Infecciones/métodos , Trabajo de Parto Inducido/métodos , Trabajo de Parto Inducido/tendencias , Servicios de Salud Materna/tendencias , Innovación Organizacional , Formulación de Políticas , Embarazo , Encuestas y Cuestionarios , Reino Unido
8.
Medicine (Baltimore) ; 100(15): e25495, 2021 Apr 16.
Artículo en Inglés | MEDLINE | ID: mdl-33847662

RESUMEN

ABSTRACT: While the new Coronavirus Disease 2019 (COVID-19) pandemic rapidly spread across the world, South America was reached later in relation to Asia, Europe and the United States of America (USA). Brazil concentrates now the largest number of cases in the continent and, as the disease speedily progressed throughout the country, prompt and challenging operational strategies had to be taken by institutions caring for COVID-19 and non-COVID-19 patients in order to assure optimal workflows, triage, and management. Although hospitals in the USA, Europe and Asia have shared their experience on this subject, little has been discussed about such strategies in South America or by the perspective of outpatient centers, which are paramount in the radiology field. This article shares the guidelines adopted early in the pandemic by a nationwide outpatient healthcare center composed by a network of more than 200 patient service centers and nearly 2,000 radiologists in Brazil, discussing operational and patient management strategies, staff protection, changes adopted in the fellowship program, and the effectiveness of such measures.


Asunto(s)
Atención Ambulatoria , COVID-19 , Gestión del Cambio , Defensa Civil , Vías Clínicas , Planificación Estratégica , Tecnología Radiológica , Atención Ambulatoria/métodos , Atención Ambulatoria/organización & administración , Atención Ambulatoria/estadística & datos numéricos , Brasil/epidemiología , COVID-19/diagnóstico , COVID-19/epidemiología , COVID-19/prevención & control , Defensa Civil/organización & administración , Defensa Civil/estadística & datos numéricos , Vías Clínicas/organización & administración , Vías Clínicas/tendencias , Humanos , Innovación Organizacional , Guías de Práctica Clínica como Asunto , SARS-CoV-2 , Planificación Estratégica/normas , Planificación Estratégica/estadística & datos numéricos , Tecnología Radiológica/métodos , Tecnología Radiológica/organización & administración , Tecnología Radiológica/estadística & datos numéricos
9.
Chest ; 160(1): 175-186, 2021 07.
Artículo en Inglés | MEDLINE | ID: mdl-33667491

RESUMEN

BACKGROUND: SARS-CoV-2 aerosolization during noninvasive positive-pressure ventilation may endanger health care professionals. Various circuit setups have been described to reduce virus aerosolization. However, these setups may alter ventilator performance. RESEARCH QUESTION: What are the consequences of the various suggested circuit setups on ventilator efficacy during CPAP and noninvasive ventilation (NIV)? STUDY DESIGN AND METHODS: Eight circuit setups were evaluated on a bench test model that consisted of a three-dimensional printed head and an artificial lung. Setups included a dual-limb circuit with an oronasal mask, a dual-limb circuit with a helmet interface, a single-limb circuit with a passive exhalation valve, three single-limb circuits with custom-made additional leaks, and two single-limb circuits with active exhalation valves. All setups were evaluated during NIV and CPAP. The following variables were recorded: the inspiratory flow preceding triggering of the ventilator, the inspiratory effort required to trigger the ventilator, the triggering delay, the maximal inspiratory pressure delivered by the ventilator, the tidal volume generated to the artificial lung, the total work of breathing, and the pressure-time product needed to trigger the ventilator. RESULTS: With NIV, the type of circuit setup had a significant impact on inspiratory flow preceding triggering of the ventilator (P < .0001), the inspiratory effort required to trigger the ventilator (P < .0001), the triggering delay (P < .0001), the maximal inspiratory pressure (P < .0001), the tidal volume (P = .0008), the work of breathing (P < .0001), and the pressure-time product needed to trigger the ventilator (P < .0001). Similar differences and consequences were seen with CPAP as well as with the addition of bacterial filters. Best performance was achieved with a dual-limb circuit with an oronasal mask. Worst performance was achieved with a dual-limb circuit with a helmet interface. INTERPRETATION: Ventilator performance is significantly impacted by the circuit setup. A dual-limb circuit with oronasal mask should be used preferentially.


Asunto(s)
COVID-19 , Presión de las Vías Aéreas Positiva Contínua , Transmisión de Enfermedad Infecciosa/prevención & control , Ventilación no Invasiva , Filtros de Aire , Benchmarking/métodos , COVID-19/terapia , COVID-19/transmisión , Presión de las Vías Aéreas Positiva Contínua/efectos adversos , Presión de las Vías Aéreas Positiva Contínua/instrumentación , Presión de las Vías Aéreas Positiva Contínua/métodos , Vías Clínicas/normas , Vías Clínicas/tendencias , Humanos , Transmisión de Enfermedad Infecciosa de Paciente a Profesional/prevención & control , Ventilación no Invasiva/efectos adversos , Ventilación no Invasiva/instrumentación , Ventilación no Invasiva/métodos , Proyectos de Investigación , Pruebas de Función Respiratoria/métodos , SARS-CoV-2 , Resultado del Tratamiento , Ventiladores Mecánicos
10.
Adv Ther ; 38(3): 1397-1403, 2021 03.
Artículo en Inglés | MEDLINE | ID: mdl-33590446

RESUMEN

The availability of pangenotypic direct-acting antivirals for treatment of hepatitis C (HCV) has provided an opportunity to simplify patient pathways. Recent clinical practice guidelines have recognised the need for simplification to ensure that elimination of HCV as a public health concern remains a priority. Despite the move towards simplified treatment algorithms, there remains some complexity in the recommendations for the management of genotype 3 patients with compensated cirrhosis. In an era where additional clinical trial data are not anticipated, clinical guidance should consider experience gained in real-world settings. Although more experience is required for some pangenotypic therapeutic options, on the basis of published real-world data, there is already sufficient evidence to consider a simplified approach for genotype 3 patients with compensated cirrhosis. The coronavirus disease 2019 (COVID-19) pandemic has highlighted the need to minimise the need for complex patient pathways and clinical practice guidelines need to continue to evolve in order to ensure that patient outcomes remain optimised.


Asunto(s)
COVID-19 , Control de Enfermedades Transmisibles , Vías Clínicas , Erradicación de la Enfermedad , Hepatitis C , Antivirales/farmacología , COVID-19/epidemiología , COVID-19/prevención & control , Control de Enfermedades Transmisibles/métodos , Control de Enfermedades Transmisibles/organización & administración , Vías Clínicas/normas , Vías Clínicas/tendencias , Erradicación de la Enfermedad/métodos , Erradicación de la Enfermedad/organización & administración , Salud Global/tendencias , Hepatitis C/epidemiología , Hepatitis C/terapia , Humanos , Guías de Práctica Clínica como Asunto , SARS-CoV-2
11.
Med Sci (Paris) ; 37(2): 159-166, 2021 Feb.
Artículo en Francés | MEDLINE | ID: mdl-33591259

RESUMEN

Pediatric brain cancers represent the most frequent solid tumors and the leading cause of cancer-driven mortality in children. Pediatric High Grade Gliomas display a very poor prognosis. Among these, DIPG (Diffuse Intrinsic Pontine Gliomas), localized to the brain stem, cannot benefit from a total exeresis due to this critical location and to their highly infiltrating nature. Radiotherapy remains the standard treatment against these tumors for almost five decades, and attempts to improve the prognosis of patients with chemotherapy or targeted therapies have failed. Thanks to the rise of high throughput sequencing, the knowledge of molecular alterations in pediatric gliomas strongly progressed and allowed to highlight distinct biomolecular entities and to establish more accurate diagnoses. In this review, we summarize this new information and the perspectives that it brings for clinical strategies.


TITLE: L'art de la guerre appliqué aux DIPG - Connais ton ennemi. ABSTRACT: Les tumeurs cérébrales pédiatriques représentent la principale cause de mortalité par cancer chez l'enfant. Alors que l'exérèse complète a une valeur pronostique dans certains gliomes de haut grade, les DIPG (diffuse intrinsic pontine gliomas) ne peuvent en bénéficier du fait d'une localisation critique au niveau du tronc cérébral et de leur caractère infiltrant. La radiothérapie demeure le traitement de référence contre ces tumeurs depuis bientôt cinquante ans, et les tentatives pour améliorer le pronostic vital des patients à l'aide de chimiothérapies ou de thérapies ciblées se sont révélées infructueuses. La connaissance des altérations moléculaires dans ces gliomes a fortement progressé cette dernière décennie, grâce aux progrès du séquençage à haut débit. Cela a permis de révéler des entités distinctes au niveau moléculaire et de préciser des diagnostics discriminants. Dans cette revue, nous faisons le point sur ces nouvelles connaissances et les perspectives qu'elles apportent en termes de stratégies cliniques.


Asunto(s)
Neoplasias Encefálicas/terapia , Glioma/terapia , Oncología Médica/tendencias , Edad de Inicio , Neoplasias Encefálicas/epidemiología , Neoplasias Encefálicas/patología , Niño , Vías Clínicas/tendencias , Glioma/epidemiología , Glioma/patología , Humanos , Oncología Médica/métodos , Pronóstico
12.
Elife ; 102021 02 16.
Artículo en Inglés | MEDLINE | ID: mdl-33588991

RESUMEN

Before the coronavirus 2019 (COVID-19) pandemic began, antimicrobial resistance (AMR) was among the top priorities for global public health. Already a complex challenge, AMR now needs to be addressed in a changing healthcare landscape. Here, we analyse how changes due to COVID-19 in terms of antimicrobial usage, infection prevention, and health systems affect the emergence, transmission, and burden of AMR. Increased hand hygiene, decreased international travel, and decreased elective hospital procedures may reduce AMR pathogen selection and spread in the short term. However, the opposite effects may be seen if antibiotics are more widely used as standard healthcare pathways break down. Over 6 months into the COVID-19 pandemic, the dynamics of AMR remain uncertain. We call for the AMR community to keep a global perspective while designing finely tuned surveillance and research to continue to improve our preparedness and response to these intersecting public health challenges.


Asunto(s)
Antibacterianos , Tratamiento Farmacológico de COVID-19 , COVID-19 , Vías Clínicas , Farmacorresistencia Bacteriana/fisiología , Salud Global/tendencias , Antibacterianos/provisión & distribución , Antibacterianos/uso terapéutico , COVID-19/epidemiología , COVID-19/prevención & control , Control de Enfermedades Transmisibles/métodos , Control de Enfermedades Transmisibles/organización & administración , Vías Clínicas/organización & administración , Vías Clínicas/tendencias , Humanos , SARS-CoV-2
13.
Am J Kidney Dis ; 77(5): 777-785, 2021 05.
Artículo en Inglés | MEDLINE | ID: mdl-33388404

RESUMEN

The coronavirus disease 2019 (COVID-19) pandemic required transplant nephrologists, surgeons, and care teams to make decisions about the full spectrum of transplant program operations and clinical practices in the absence of experience or data. Initially, across the country, there was a reduction in kidney transplant procedures and a striking pause in the conduct of living donation and living-donor transplant surgeries. Aspects of candidate evaluation and follow-up rapidly converted to telehealth. Months into the pandemic, much has been learned from experiences worldwide, yet many questions remain. In this Perspective, we reflect on some of the practice decisions made by the transplant community in the initial response to the pandemic and consider lessons learned, including those related to the risks, benefits, and logistical considerations of proceeding with versus delaying deceased-donor transplantation, living donation, and living-donor transplantation during the pandemic. We review the evolution of therapeutic strategies for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and their use in transplant recipients, current consensus related to immunosuppression management in infected transplant recipients, and emerging information on vaccination against SARS-CoV-2. We share our thoughts on research priorities, discuss the areas in which we are still practicing with uncertainty, and look ahead to the next phase of the pandemic response.


Asunto(s)
COVID-19 , Vías Clínicas , Terapia de Inmunosupresión/métodos , Fallo Renal Crónico , Trasplante de Riñón/métodos , COVID-19/epidemiología , COVID-19/prevención & control , Toma de Decisiones Clínicas , Vías Clínicas/organización & administración , Vías Clínicas/tendencias , Humanos , Control de Infecciones/métodos , Fallo Renal Crónico/epidemiología , Fallo Renal Crónico/cirugía , SARS-CoV-2 , Telemedicina/métodos , Tiempo de Tratamiento , Donantes de Tejidos/estadística & datos numéricos , Receptores de Trasplantes
14.
J Intensive Care Med ; 36(5): 612-616, 2021 May.
Artículo en Inglés | MEDLINE | ID: mdl-33323033

RESUMEN

BACKGROUND: Covid-19 pandemic has resulted in the development of severe and persistent respiratory failure requiring long term ventilatory support. This necessitates the need for a reliable and easy to implement tracheostomy protocol given the concern for viral transmission risk to the involved healthcare personnel due to the aerosol generating nature of the procedure. We describe a protocol with unique and novel modifications to the Ciaglia dilatational percutaneous tracheostomy, effectively implemented during the Covid-19 pandemic at our institution. METHODS: We describe the baseline characteristics of our initial 11 patients who underwent the procedure. Outlined are the healthcare personnel involved and the steps which are organized into 4 phases: planning, pre-procedure, intra-procedure and post-procedure. We have tracked procedural duration, provider safety as well as the development of new complications. RESULTS: We describe use of this protocol for 11 bedside percutaneous tracheostomies performed on patients with COVID-19. The average total procedural duration as well as incision to tracheostomy tube placement times was 32.6 minutes and 5.8 minutes respectively. All 3 providers performing the tracheostomies remained asymptomatic with negative COVID-19 RT-PCR testing at 3 weeks. CONCLUSIONS: We report an efficacious and adaptable protocol for elective bedside percutaneous tracheostomies for patients with persistent ventilatory requirements due to COVID-19 with an intent to provide standardized and safe care for the patient and the involved healthcare personnel.


Asunto(s)
COVID-19 , Vías Clínicas , Exposición Profesional/prevención & control , Equipo de Protección Personal/normas , Insuficiencia Respiratoria , Traqueostomía , COVID-19/complicaciones , COVID-19/fisiopatología , COVID-19/prevención & control , Vías Clínicas/organización & administración , Vías Clínicas/tendencias , Femenino , Personal de Salud , Humanos , Control de Infecciones/métodos , Masculino , Persona de Mediana Edad , Grupo de Atención al Paciente/organización & administración , Prueba de Estudio Conceptual , Insuficiencia Respiratoria/etiología , Insuficiencia Respiratoria/terapia , SARS-CoV-2/aislamiento & purificación , Administración de la Seguridad , Traqueostomía/métodos , Traqueostomía/tendencias , Estados Unidos
15.
Postgrad Med J ; 97(1147): 280-285, 2021 May.
Artículo en Inglés | MEDLINE | ID: mdl-32371406

RESUMEN

STUDY PURPOSE: Out-of-hospital cardiac arrests (OHCA) in the young population have only been examined in a limited number of regional studies. Hence, we sought to describe OHCA characteristics and predictors of survival to hospital discharge for the young Irish population. STUDY DESIGN: An observational analysis of the national Irish OHCA register for all OHCAs aged ≤35 years between January 2012 and December 2017 was performed. The young population was categorised into three age groups: ≤1 year, 1-15 years and 16-35 years. Multivariable logistic regression was used to determine the independent predictors of survival to hospital discharge. RESULTS: A total of 1295 OHCAs aged ≤35 years (26.9% female, median age 25 (IQR 17-31)) had resuscitation attempted. OHCAs in those aged ≥16 years (n=1005) were more likely to happen outside the home (38.5% vs 22.8%, p<0.001) and be of non-medical aetiology (59% vs 27.6%, p<0.001) compared with those aged <16 years (n=290). Asphyxiation, trauma and drug overdoses accounted for over 90% of the non-medical OHCAs for those 16-35 years. Overall survival to hospital discharge for the cohort was 5.1%; survival was non-significantly higher for those aged 16-35 years compared with those aged 1-15 years (6.0%, vs 2.8% p=0.93). Independent predictors of survival to hospital discharge included bystander witnessed OHCA, a shockable initial rhythm and a bystander defibrillation attempt. CONCLUSIONS: The high prevalence of non-medical OHCAs and the OHCA location need to be considered when developing OHCA care pathways and preventative strategies to reduce the burden of OHCAs in the young population.


Asunto(s)
Asfixia/complicaciones , Vías Clínicas/tendencias , Sobredosis de Droga/complicaciones , Servicios Médicos de Urgencia , Paro Cardíaco Extrahospitalario , Heridas y Lesiones/complicaciones , Adolescente , Adulto , Asfixia/epidemiología , Asfixia/prevención & control , Reanimación Cardiopulmonar/métodos , Sobredosis de Droga/epidemiología , Sobredosis de Droga/prevención & control , Servicios Médicos de Urgencia/métodos , Servicios Médicos de Urgencia/organización & administración , Servicios Médicos de Urgencia/normas , Femenino , Humanos , Lactante , Irlanda/epidemiología , Masculino , Paro Cardíaco Extrahospitalario/etiología , Paro Cardíaco Extrahospitalario/mortalidad , Paro Cardíaco Extrahospitalario/terapia , Alta del Paciente/estadística & datos numéricos , Servicios Preventivos de Salud , Mejoramiento de la Calidad , Sistema de Registros/estadística & datos numéricos , Análisis de Supervivencia , Heridas y Lesiones/epidemiología , Heridas y Lesiones/prevención & control
17.
Vascular ; 29(5): 751-761, 2021 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-33249975

RESUMEN

OBJECTIVES: Iliofemoral deep venous thrombosis is associated with an increased risk of developing post-thrombotic syndrome resulting in reduced quality of life. As there is debate about best management practices, this study aimed to examine the referral and treatment pathways for patients presenting with iliofemoral deep venous thrombosis over an 11-year period at our institution. METHODS: We conducted a retrospective review of patients diagnosed with lower limb deep vein thrombosis between 2010 and 2020. Ultrasound report findings were reviewed for the presence of iliofemoral deep venous thrombosis with acute, occlusive, or proximal clot. Multiple factors were extracted, including patient demographics, risk factors, diagnostic methods, interventions, referrals, and details of follow-up. The CaVenT and ATTRACT trials studied the benefit of thrombolysis in the early phase of iliofemoral deep venous thrombosis management as compared to anticoagulation alone. An analysis was conducted of patients requiring thrombolysis to determine whether these trials impacted physician practice patterns for thrombolysis. Data were organized and examined by year for trends in treatment and referral pathways. RESULTS: The review yielded 2792 patients assessed for lower limb deep venous thrombosis by ultrasound. Four hundred and sixty-seven (16.7%) patients were confirmed to have an occlusive iliofemoral deep venous thrombosis. The average age was 62.7 years (18-101 years). Half (50.4%) of the patients were male. The most common etiology for clot was malignancy-induced hypercoagulable state (39.0%). There was no difference in incidence of iliofemoral deep venous thrombosis diagnosed by ultrasound per year, with an average of 42.5 per year and a peak of 61. There was a trend towards increased rates of computed tomography imaging, ranging between 9.1% and 52.9%. The rate thrombolysis per year ranged between 1.8% and 8.9%, with a range of 4.3% (n = 20) to 8.9% (n = 5) in 2018. The use of pharmacomechanical thrombolysis increased, from 25% (n = 1) in 2010-2012 to 87.5% (n = 7) in 2018-2020. The rate of inferior vena cava filter insertion alone decreased from 18.2% in 2010 (n = 4) to 5.9% (n = 1) in 2020. The length of thrombolysis treatment also decreased, from 100% of patients (n = 4) receiving treatment duration greater than 24 h in 2010-2012 to 0% (n = 0) in 2018-2020. About 45% of patients receiving thrombolysis (n = 9) had venous stenting. No difference in treatment outcomes were observed, with greater than 87.5% of patients reaching intermediate to full resolution of clot burden. No patients experienced intracranial hemorrhage. CONCLUSIONS: The results of this analysis highlight the change in practice in our institution over time. The low rate of intervention likely reflects the current lack of consensus in published guidelines. It is important for future work to elicit the most appropriate management pathways for patients with iliofemoral deep venous thrombosis.


Asunto(s)
Anticoagulantes/uso terapéutico , Vías Clínicas/tendencias , Procedimientos Endovasculares/tendencias , Vena Femoral , Vena Ilíaca , Evaluación de Procesos y Resultados en Atención de Salud/tendencias , Pautas de la Práctica en Medicina/tendencias , Derivación y Consulta/tendencias , Terapia Trombolítica/tendencias , Trombosis de la Vena/terapia , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Anticoagulantes/efectos adversos , Procedimientos Endovasculares/efectos adversos , Procedimientos Endovasculares/instrumentación , Femenino , Vena Femoral/diagnóstico por imagen , Humanos , Vena Ilíaca/diagnóstico por imagen , Incidencia , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Factores de Riesgo , Stents/tendencias , Terapia Trombolítica/efectos adversos , Factores de Tiempo , Resultado del Tratamiento , Trombosis de la Vena/diagnóstico por imagen , Trombosis de la Vena/epidemiología , Adulto Joven
18.
J Plast Reconstr Aesthet Surg ; 74(3): 644-710, 2021 03.
Artículo en Inglés | MEDLINE | ID: mdl-33221182

RESUMEN

During the recovery restitution phase of the coronavirus pandemic, breast reconstruction teams have faced particular challenges to restarting this essential service. This is due to the length and complexity of the surgery, along with the demands on healthcare staff. The Royal College of Surgeons have classified immediate breast reconstruction as priority 2 and the National Institute for Health and Care Excellence have provided a pre-operative pathway for resumption of elective procedures. We therefore describe our experience in restarting our service for providing a breast reconstruction service from the 29th June 2020.


Asunto(s)
Neoplasias de la Mama , COVID-19 , Vías Clínicas , Procedimientos Quirúrgicos Electivos , Mamoplastia , Neoplasias de la Mama/epidemiología , Neoplasias de la Mama/cirugía , COVID-19/epidemiología , COVID-19/prevención & control , Vías Clínicas/organización & administración , Vías Clínicas/tendencias , Procedimientos Quirúrgicos Electivos/métodos , Procedimientos Quirúrgicos Electivos/estadística & datos numéricos , Femenino , Humanos , Control de Infecciones/métodos , Control de Infecciones/organización & administración , Mamoplastia/métodos , Mamoplastia/estadística & datos numéricos , Innovación Organizacional , Evaluación de Procesos y Resultados en Atención de Salud , SARS-CoV-2 , Medicina Estatal/organización & administración , Medicina Estatal/tendencias , Reino Unido/epidemiología
20.
J Plast Reconstr Aesthet Surg ; 74(3): 644-710, 2021 03.
Artículo en Inglés | MEDLINE | ID: mdl-33199221

RESUMEN

The SARS-CoV-2 cornovirus disease (COVID-19) pandemic has significantly affected referrals of new suspected cancers from primary care to specialist services in the National Health Service (NHS) across the UK.  Amongst the many factors causing delay, such as fear and uncertainty about COVID-19 transmission, reluctance to seek medical attention for cancer sypmtoms and avoiding additional pressure on NHS services, we anticipate a surge in urgent skin cancer referrals to our plastic surgery service as we enter a post-COVID recovery phase.  On the basis of previous referral data and statistical forecasting, we share our predicted numbers against our actual number of urgent skin cancer referrals for the COVID-19 period and, based on this analysis, encourage all cancer services to prepare and allocate resources appropriately for the busy months to follow.


Asunto(s)
COVID-19 , Derivación y Consulta , Neoplasias Cutáneas , Cirugía Plástica , Tiempo de Tratamiento/estadística & datos numéricos , COVID-19/epidemiología , COVID-19/prevención & control , COVID-19/psicología , Vías Clínicas/tendencias , Detección Precoz del Cáncer/métodos , Detección Precoz del Cáncer/normas , Mal Uso de los Servicios de Salud/prevención & control , Mal Uso de los Servicios de Salud/estadística & datos numéricos , Humanos , Control de Infecciones/métodos , Control de Infecciones/organización & administración , Evaluación de Necesidades , Derivación y Consulta/organización & administración , Derivación y Consulta/tendencias , SARS-CoV-2 , Neoplasias Cutáneas/diagnóstico , Neoplasias Cutáneas/epidemiología , Neoplasias Cutáneas/cirugía , Cirugía Plástica/métodos , Cirugía Plástica/organización & administración , Cirugía Plástica/tendencias , Reino Unido/epidemiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA